Optimization of Glucocorticoid Taper Strategies for SLE-ITP

Launched by FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL · Aug 16, 2022

Keywords

ClinConnect Summary

Complete response was defined as a platelet count ≥100x10\^9/L and the absence of bleeding and new other symptoms.Complete response would be confirmed by platelet counts on 2 separate occasions 7 days apart. Adequate glucocorticoids treatment was defined as at least a dose 50mg/day of prednisone (or equivalent glucocorticoids) for patients with weight less than 50kg, 60mg/day for patients with weight 50-75kg , 75mg/day for patients with weight more than 75kg. Adequate glucocorticoids were used for induction, and the total duration of adequate glucocorticoids treatment for patients enrolled ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women aged 14-75 (including 14 and 75);
• • 2. It meets the 2012 Systemic lupus Erythematosus International Collaborative Group (SLICC) classification criteria or the 2019 ACR and European Society of Rheumatology (EULAR) classification criteria ;
• • 3. severe SLE-ITP patients with PLT≤30x10\^9/L at onset and complete response (PLT ≥100x10\^9/L) after induction therapy within 3 weeks;
• • 4. Prior to the commencement of any study-specific procedure, the patient or legal representative must provide signed and dated written informed consent.
• Exclusion Criteria:
• • 1. Relapse in the presence of glucocorticoid and/or immunosuppressive maintenance therapy;
• • 2. Combined with antiphospholipid syndrome;
• • 3. Combined with other important organ damage such as lupus nephritis, neuropsychiatric lupus;
• • 4. Coexisting immune diseases require glucocorticoid and/or immunosuppressive therapy;
• • 5. There are serious comorbidities affecting treatment such as diabetes, severe hypertension, coronary heart disease;
• • 6. self-evaluation affected by poor understanding ability, vision decline and other reasons ;
• • 7. Poor adherence and failure to adhere to treatment as prescribed. -